RP 1208
Alternative Names: RP-1208Latest Information Update: 23 Nov 2022
At a glance
- Originator Reviva Pharmaceuticals
- Class Antidepressants; Obesity therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Depressive disorders; Obesity
Most Recent Events
- 23 Nov 2022 Reviva Pharmaceuticals receives issuance of patent for composition of matter patent for RP 1208 in Canada, United States, Europe, China, and Japan
- 11 Mar 2021 RP 1208 is available for licensing as of 11 Mar 2021. https://revivapharma.com/
- 11 Mar 2021 Reviva Pharmaceuticals has patent protection for RP 1208 in the US and Europe